Page last updated: 2024-10-28

guanfacine and Suicidal Ideation

guanfacine has been researched along with Suicidal Ideation in 3 studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Suicidal Ideation: A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.

Research Excerpts

ExcerptRelevanceReference
"Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks."6.84Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. ( Albano, AM; Compton, SN; Hamdani, M; Robertson, B; Rynn, MA; Strawn, JR, 2017)
"Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks."2.84Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. ( Albano, AM; Compton, SN; Hamdani, M; Robertson, B; Rynn, MA; Strawn, JR, 2017)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Nikou, AF1
Lai, M1
Solmssen, C1
Bhargava, M1
Ben-David, K1
Ramsubick, C1
Rice, T2
Coffey, B1
Weiss-Goldman, N1
Arditi, B1
Coffey, BJ1
Strawn, JR1
Compton, SN1
Robertson, B1
Albano, AM1
Hamdani, M1
Rynn, MA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).[NCT01470469]Phase 283 participants (Actual)Interventional2012-01-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Diastolic Blood Pressure at Up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

InterventionmmHg (Mean)
PLACEBO0.9
SPD503-1.3

Change From Baseline in ECG QTcF Interval at up to 12 Weeks

The QT interval is the time from the start of the Q wave to the end of the T wave. It is a portion of the ECG tracing that represents the time taken for ventricular depolarisation and repolarisation. The QTcF includes a correction factor to help account for changes in heart rate. (NCT01470469)
Timeframe: Baseline and up to 12 weeks

Interventionmsec (Mean)
PLACEBO0.3
SPD5034.1

Change From Baseline in Electrocardiogram (ECG) QRS Interval at up to 12 Weeks

QRS complex is a portion of the ECG tracing that represents depolarization of the ventricular myocardium. (NCT01470469)
Timeframe: Baseline and up to 12 weeks

Interventionmsec (Mean)
PLACEBO0.7
SPD5030.1

Change From Baseline in Height at up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Interventioncm (Mean)
PLACEBO0.5
SPD5031.0

Change From Baseline in Pulse Rate at Up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Interventionbeats/min (Mean)
PLACEBO-0.5
SPD503-1.8

Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

InterventionmmHg (Mean)
PLACEBO-1.7
SPD503-2.3

Change From Baseline in Weight at up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Interventionkg (Mean)
PLACEBO0.7
SPD5031.3

Trials

1 trial available for guanfacine and Suicidal Ideation

ArticleYear
Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial.
    Journal of child and adolescent psychopharmacology, 2017, Volume: 27, Issue:1

    Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anxiety Disorders; Anxiety, Separation; Child; Del

2017

Other Studies

2 other studies available for guanfacine and Suicidal Ideation

ArticleYear
Topiramate for Posttraumatic Symptoms in an Obese Adolescent Girl.
    Journal of child and adolescent psychopharmacology, 2021, Volume: 31, Issue:3

    Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antipsychotic Agents; Depression;

2021
Psychopharmacology of the Rage Attack Phenomenon in a Child with Obsessive Compulsive Disorder.
    Journal of child and adolescent psychopharmacology, 2018, Volume: 28, Issue:5

    Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Fem

2018